Citations

Clear

6273 citation(s) found for "To, Andrew".

Detection of 1α,25-Dihydroxyvitamin D-Regulated miRNAs in Zebrafish by Whole Transcriptome Sequencing
Craig, Theodore A., Zhang, Yuji , Magis, Andrew T. , Funk, Cory C. , Price, Nathan D. , Ekker, Stephen C. , Kumar, Rajiv , Price, Nathan D , Ekker, Stephen C , Kumar, Rajiv

Mayo Clinic

Zebrafish | March 20, 2014 | Volume: 11 | Issue: 3 | Pages: 207-218

10.1089/zeb.2013.0899 | PMID 24650217 Get It

Proficiency of nerve conduction using standard methods and reference values (cl. NPhys Trial 4)
Litchy, William J. , Albers, James W., Wolfe, James, Bolton, Charles F., WALSH, NANCY, Klein, Christopher J. , Zafft, Andrew J., Russell, James W. , Zwirlein, Melanie, Overland, Carol J., Davies, Jenny L., Carter, Rickey E. , Dyck, P. James B. , Investigators, the CI. Nphys Trial 4, Tesfaye, Solomon , Investigators, the CI. Nphys Trial 4, Klein, Christopher J , Carter, Rickey E

Mayo Clinic

Muscle & Nerve | March 19, 2014 | Volume: 50 | Issue: 6 | Pages: 900-908

10.1002/mus.24243 | PMID 24644133 Get It

ABSTRACTIntroductionThe Cl. NPhys Trial 3 showed that attributes of nerve conduction (NC) were without significant intraobserver differences, although there were significant interobserver differences. Methods: Trial 4 tested whether use of written instructions and pretrial agreement on techniques and use of standard reference values, diagnostic percentile values, or broader categorization of abnormality could reduce significant interobserver disagreement and improve agreement among clinical neurophysiologists. Results: The Trial 4 modifications markedly decreased, but did not eliminate, significant interobserver differences of measured attributes of NC. Use of standard reference values and defined percentile values of abnormality decreased interobserver disagreement and improved agreement of judgment of abnormality among evaluators. Therefore, the same clinical neurophysiologist should perform repeat NCs of therapeutic trial patients. Conclusions: Differences in interobserver judgment of abnormality decrease with use of common standard reference values and a defined percentile level of abnormality, providing a rationale for their use in therapeutic trials and medical practice. Muscle Nerve 50: 900–908, 2014
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents
West, Andrew B. , Cowell, Rita M. , Daher, João Paulo Lima , Moehle, Mark S. , Hinkle, Kelly M., Melrose, Heather L. , Standaert, David G. , Volpicelli‐Daley, Laura A.

Mayo Clinic

Journal of Comparative Neurology | March 14, 2014 | Volume: 522 | Issue: 11 | Pages: 2465-2480

10.1002/cne.23583 | PMID 24633735 Get It

ABSTRACTMutations in leucine‐rich repeat kinase 2 (LRRK2) are found in a significant proportion of late‐onset Parkinson's disease (PD) patients. Elucidating the neuroanatomical localization of LRRK2 will further define LRRK2 function and the molecular basis of PD. Here, we utilize recently characterized monoclonal antibodies to evaluate LRRK2 expression in rodent brain regions relevant to PD. In both mice and rats, LRRK2 is highly expressed in the cortex and striatum, particularly in pyramidal neurons of layer V and in medium spiny neurons within striosomes. Overall, rats have a more restricted distribution of LRRK2 compared with mice. Mice, but not rats, show high levels of LRRK2 expression in the substantia nigra pars compacta. Expression of the pathogenic LRRK2‐G2019S protein from mouse bacterial artificial chromosome (BAC) constructs closely mimics endogenous LRRK2 distribution in the mouse brain. However, LRRK2‐G2019S expression derived from human BAC constructs causes LRRK2 to be expressed in additional neuron subtypes in the rat such as striatal cholinergic interneurons and the substantia nigra pars compacta. The distribution of LRRK2 from human BAC constructs more closely resembles descriptions of LRRK2 in humans and nonhuman primates. Computational analyses of DNA regulatory elements in LRRK2 show a primate‐specific promoter sequence that does not exist in lower mammalian species. These noncoding regions may be involved in directing neuronal expression patterns. Together, these studies will aid in understanding the normal function of LRRK2 in the brain and will assist in model selection for future studies. J. Comp. Neurol. 522:2465–2480, 2014. © 2014 Wiley Periodicals, Inc.
PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome
Régal, Luc , Shen, Xin‐Ming , Selcen, Duygu , Verhille, Chantal, Meulemans, Sandra, Creemers, John W.M. , Engel, Andrew G.

Mayo Clinic

Neurology | March 8, 2014 | Volume: 82 | Issue: 14 | Pages: 1254-1260

10.1212/wnl.0000000000000295 | PMID 24610330 Get It

Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studies
Kramer, Lynn D., Satlin, Andrew , French, Jacqueline A. , Perucca, Emilio , Ben‐Menachem, Elinor , Kwan, Patrick , Shih, Jerry J. , Laurenza, Antonio, Yang, Haichen, Zhu, Jin , Squillacote, David, Krauss, Gregory L. , Perucca, Emilio , French, Jacqueline

Mayo Clinic

Epilepsia | March 7, 2014 | Volume: 55 | Issue: 3 | Pages: 423-431

10.1111/epi.12527 | PMID 24605793 Get It

SummaryObjectiveTo better understand the relationship between efficacy and perampanel dose, integrated actual (last) dose data from three phase III trials and an extension study (blinded Conversion Period; open‐label Maintenance Period) were analyzed.MethodsSeizure frequency data were analyzed in patients who were randomized to and completed the 13‐week Maintenance Period of the phase III studies on perampanel 8 mg, and who received an actual (last) dose of 12 mg during (1) the extension 16‐week blinded Conversion Period or (2) weeks 1–13 of the extension Maintenance Period. Due to a treatment‐by‐region interaction (p = 0.042), analyses excluded patients from the Latin America region (n = 162/1,480; 10.9% of the treated cohort).ResultsOf 372 patients randomized to 8 mg in the phase III studies, 273 completed the Maintenance Period at 8 mg and 267 entered the extension study. In patients who then had an actual (last) dose of 12 mg during the extension blinded Conversion Period (n = 217), median percent change in seizure frequency per 28 days improved from −32.4% (8 mg, phase III Maintenance Period) to −44.2% (12 mg, extension blinded Conversion Period); 50% responder rates increased slightly from 37.3% to 42.9%. In patients who completed the phase III studies on 8 mg and had an actual (last) dose of 12 mg during weeks 1–13 of the extension Maintenance Period (n = 181), median percent change in seizure frequency per 28 days improved from −34.1% (phase III Maintenance Period) to −46.0% (weeks 1–13 extension Maintenance Period); 50% responder rates were 39.2% and 46.4%. Seizure control remained substantially unchanged in patients who completed the phase III studies at 12 mg and continued on that dose during the extension.SignificanceIncreasing perampanel dose from 8 to 12 mg can produce additional benefits in seizure control in at least some patients who tolerate the higher dose.
Faculty Opinions recommendation of Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus.
Badley, Andrew D. , Cummins, Nathan W.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 3, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718264442.793491515 Get It

Two‐year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial
Heck, Christianne, King‐Stephens, David , Nair, Dileep , Jobst, Barbara C. , Barkley, Gregory L., Salanova, Vicenta , Gwinn, Ryder P. , Skidmore, Christopher , Ness, Paul C. Van, Bergey, Gregory K. , Park, Yong D., Miller, Ian , Geller, Eric B., Rutecki, Paul , Zimmerman, Richard S. , Spencer, David , Leiphart, James W., Wharen, Robert E. , Fessler, James, Fountain, Nathan B. , Eisenschenk, Stephan, Duckrow, Robert B., Hirsch, Lawrence J. , Bazil, Carl W., O’Donovan, Cormac A. , Sun, Felice T., Courtney, Tracy A., Seale, Cairn G. , Morrell, Martha J. , Massey, Andrew D. , Cole, Andrew J. , Smith, Michael C. F. , Goldman, Alica M. , Edwards, Jonathan , Worrell, Gregory A. , Gross, Robert E. , Fountain, Nathan , Hirsch, Lawrence J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | February 24, 2014 | Volume: 55 | Issue: 3 | Pages: 432-441

10.1111/epi.12534 | PMID 24621228 Get It

Summary Objective To demonstrate the safety and effectiveness of responsive stimulation at the seizure focus as an adjunctive therapy to reduce the frequency of seizures in adults with medically intractable partial onset seizures arising from one or two seizure foci. Methods Randomized multicenter double‐blinded controlled trial of responsive focal cortical stimulation (RNS System). Subjects with medically intractable partial onset seizures from one or two foci were implanted, and 1 month postimplant were randomized 1:1 to active or sham stimulation. After the fifth postimplant month, all subjects received responsive stimulation in an open label period ( OLP ) to complete 2 years of postimplant follow‐up. Results All 191 subjects were randomized. The percent change in seizures at the end of the blinded period was −37.9% in the active and −17.3% in the sham stimulation group (p = 0.012, Generalized Estimating Equations). The median percent reduction in seizures in the OLP was 44% at 1 year and 53% at 2 years, which represents a progressive and significant improvement with time (p < 0.0001). The serious adverse event rate was not different between subjects receiving active and sham stimulation. Adverse events were consistent with the known risks of an implanted medical device, seizures, and of other epilepsy treatments. There were no adverse effects on neuropsychological function or mood. Significance Responsive stimulation to the seizure focus reduced the frequency of partial‐onset seizures acutely, showed improving seizure reduction over time, was well tolerated, and was acceptably safe. The RNS System provides an additional treatment option for patients with medically intractable partial‐onset seizures.
How common are myeloproliferative neoplasms? A systematic review and meta‐analysis
Titmarsh, Glen J., Duncombe, Andrew , O’Rorke, Michael , Vocht, Frank de , Horan, Sarah, Fritschi, Lin , Clarke, Mike, Anderson, Lesley , McMullin, Mary Frances , Mesa, Ruben A. , Clarke, Mike, Anderson, Lesley A , Fritschi, Lin

Mayo Clinic

American Journal of Hematology | February 12, 2014 | Volume: 89 | Issue: 6 | Pages: 581-587

10.1002/ajh.23690 | PMID 24971434 Get It

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta‐analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty‐four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1–99.8%) and evidence of publication bias for ET and PMF (Egger test, P = 0.007 and P ≤ 0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. Am. J. Hematol. 89:581–587, 2014. © 2014 Wiley Periodicals, Inc.